Fu X, Rezapour M, Wu X, Li L, Sjögren C, Ulmsten U
Department of Obstetrics and Gynecology, Institute of Women's and Children's Health, Division of Obstetrics and Gynecology, Uppsala University, 751 85 Uppsala, Sweden.
Int Urogynecol J Pelvic Floor Dysfunct. 2003 Oct;14(4):276-81; discussion 281. doi: 10.1007/s00192-003-1042-7. Epub 2003 Aug 2.
Our objective was to study the expression of estrogen receptor (ER) isoforms, ER-alpha and ER-beta, in the anterior vaginal wall of menopausal and fertile women with genuine stress incontinence (SI) by immunohistochemistry and Western blot analysis. Eighteen menopausal women with SI who either were or were not taking estrogen/progestin replacement therapy and 14 fertile women with SI who either were or were not taking contraceptives were enrolled in the study. Biopsies from the suburethral anterior vaginal wall were obtained at tension-free vaginal tape (TVT) operation. Monoclonal antibody to ER-alpha and polyclonal antibody to ER-beta were used to stain frozen sections of vaginal tissue. The receptor expressions were scored based on percentage of positive cells. ER-alpha was detected in vaginal epithelial, stromal and smooth muscle cells. In menopausal SI women ER-alpha was detected significantly more frequently in the vaginal walls of estrogen/progestin-treated patients than in those who were untreated. Fertile SI women had significantly higher expression of ER-alpha than menopausal SI women. ER-alpha was not observed in vaginal blood vessels. ER-beta was detected in epithelial and vascular smooth muscle cells of the vagina. No significant difference in ER-beta expression was observed between different groups of patients. The expression of ER-alpha was not correlated with that of ER-beta. Both ER-alpha and -beta were detected, indicating a potential role for both types of estrogen receptor in the human vaginal wall. The expression of ER-alpha, but not of ER-beta, in menopausal SI women was regulated by estrogen/progestin replacement therapy. The presence of ER-beta in vaginal vascular smooth muscle cells raises the possibility of vascular effects of estrogen on the human vaginal wall.
我们的目的是通过免疫组织化学和蛋白质印迹分析,研究雌激素受体(ER)亚型α-ER和β-ER在绝经和有生育能力的真性压力性尿失禁(SI)女性阴道前壁中的表达。18名患有SI的绝经女性(其中部分正在接受或未接受雌激素/孕激素替代治疗)和14名患有SI的有生育能力的女性(其中部分正在服用或未服用避孕药)被纳入研究。在无张力阴道吊带(TVT)手术时获取尿道下阴道前壁的活检组织。使用抗α-ER单克隆抗体和抗β-ER多克隆抗体对阴道组织冰冻切片进行染色。根据阳性细胞百分比对受体表达进行评分。在阴道上皮细胞、基质细胞和平滑肌细胞中检测到α-ER。在绝经后SI女性中,接受雌激素/孕激素治疗患者的阴道壁中α-ER的检测频率明显高于未治疗患者。有生育能力的SI女性的α-ER表达明显高于绝经后SI女性。在阴道血管中未观察到α-ER。在阴道上皮细胞和血管平滑肌细胞中检测到β-ER。不同组患者之间β-ER表达未观察到显著差异。α-ER的表达与β-ER的表达不相关。α-ER和β-ER均被检测到,表明两种类型的雌激素受体在人阴道壁中都可能发挥作用。绝经后SI女性中α-ER的表达受雌激素/孕激素替代治疗的调节,而β-ER不受其调节。阴道血管平滑肌细胞中存在β-ER增加了雌激素对人阴道壁产生血管效应的可能性。